Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Merger or Acquisition (November 2024)
14 slides from Telix Pharmaceuticals's merger presentation, Nov 19, 2024
Slide 1: Adding FAP-Targeting Candidates to Theranostic Pipeline
Adding FAP-Targeting Candidates to Theranostic Pipeline Investor Presentation November 2024 ASX: TLX | NASDAQ: TLX 3D rendering of cancer associated fibroblast layer of tumour microenvironment.
Slide 2: Disclaimer
Disclaimer This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our we
Slide 3: Transaction to add clinically-validated FAP assets to pipeline
Transaction to add clinically-validated FAP assets to pipeline A promising pan-cancer target with initial focus on bladder cancer Next generation of • Fibroblast Activation Protein (FAP) is one of the most Deal summary FAP-targeting exciting targets in nuclear medicine – expressed in over theranosti
Slide 4: FAP: The Achilles' heel of cancer?
FAP: The Achilles’ heel of cancer? Targeting key players in the tumour microenvironment (TME) Dx/Tx FAP CAF Fibroblasts are cells Cancer cells CAFs are marked by which help to form can ‘manipulate’ significantly increased connective tissue and normal fibroblasts to levels of Fibroblast promote the b
Slide 5: The theranostic potential of FAP
The theranostic potential of FAP Using radiation to image, damage or destroy cancer cells FAP Imaging in bladder cancer exemplifies Overexpressed Combined treatment potential for therapeutic approach in cancer options FAP is highly expressed in the Weakening of the cancer TME of epithelial cancers,
Slide 6: Cracking therapeutics: A new way to target FAP
Cracking therapeutics: A new way to target FAP New assets have potential to overcome key challenges First-generation FAP-targeting candidates limited by short tumour residence Clinically validated for safety profile and Telix’s next generation candidates have a novel design enabling: efficacy in sev
Slide 7: Clinical evidence for acquired next-gen compounds
Clinical evidence for acquired next-gen compounds Proof-of-concept in-human study and extensive compassionate use Published data demonstrates therapeutic potential1 Extensive clinical data Pan-cancer uses 68Ga-DOTA.SA.FAPi PET/CT Successful proof of Used as therapy in >120 concept across diagnostic,
Slide 8: Compelling responses seen in late-stage cancer patients
Compelling responses seen in late-stage cancer patients Significant tumour mass reduction following treatment with therapeutic candidate Patient with breast cancer1 FDG-PET confirms tumour mass reduction Before in same patient After Before After Treatment with 177Lu-based, FAP-targeted therapeutic c
Slide 9: Clinical development led by renowned KOLs
Clinical development led by renowned KOLs Broad community of supporters leading investigations Frank Roesch, PhD Chandrasekhar Bal, MD & Mainz, DE Sanjana Ballal, PhD New Delhi, IN • Renowned radiochemist in • Extensive clinical experience nuclear medicine with all Roesch compounds • Invented the 68
Slide 10: Unmet need in bladder cancer
Unmet need in bladder cancer 6th most common cancer in the U.S., significant unmet need Large market opportunity White space opportunity for TRT 5, including FAP-targeting agents 83K 29% No approved systemic radionuclide therapy new cases and 16K+ deaths of patients develop Studies suggest FAP expre
Slide 11: Adding to the bladder cancer therapy toolbox
Adding to the bladder cancer therapy toolbox Complements Telix's CAIX program, options for localised and disseminated disease Trials of TLX250-CDx in bladder cancer TLX250-CDx-PET CT PERTINENCE (IIT) ZiP-UP (IIT) Alpha candidate in Exploring indication non-muscle expansion for invasive bladder TLX25
Slide 12: Pan-cancer: "Double hit" at TME – targeting hypoxia and fibrosis
Pan-cancer: “Double hit” at TME – targeting hypoxia and fibrosis A complementary approach – and a “shot in the arm” to immuno-oncology Two well validated targets with pan-cancer potential1, 2 FAP targeting FAP CAIX small molecule (fibrosis / stroma) Glioblastoma Multiforme Head and Neck Carcinoma Na
Slide 13: In summary: An exciting asset with big potential
In summary: An exciting asset with big potential Adds to urology pipeline with ability to expand to other cancer types • Clinically validated theranostic drug candidates SNMMI Image targeting FAP – a highly promising target of the Year 2019 • Next-generation compounds with longer tumour retention th
Slide 14: Contact details
Contact details: Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com A confocal microscopy image of a fibroblast. Credit: National Cancer Institute.
Telix Pharmaceuticals — Merger or Acquisition (November 2024) on 6ix